View Older Stories View More Recent Stories

Mar 18, 2020 04:25PM Pfizer Postpones Investor Day Scheduled for March 31, 2020 Due to Coronavirus Concerns
Mar 18, 2020 04:18PM Pfizer (PFE) Announces Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults Aged 18 Years or Older
Mar 18, 2020 04:17PM Pfizer (PFE) Phase 3 trial of abrocitinib for moderate to severe atopic dermatitis met all co-primary endpoints
Mar 18, 2020 04:15PM Pfizer Announces Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults Aged 18 Years or Older
Mar 18, 2020 04:15PM  Pfizer Announces Positive Top-Line Results from Third Phase 3 Trial of Abrocitinib for Moderate to Severe Atopic Dermatitis, Which Showed Improvements in Skin Clearance, Disease Extent and Severity,
Mar 17, 2020 10:00AM Pfizer Invites Public to View and Listen to Webcast of April 28 Conference Call with Analysts
Mar 17, 2020 06:13AM Pfizer (PFE) and BioNTech SE (BNTX) Agree to Co-Develop Potential COVID-19 Vaccine
Mar 17, 2020 02:02AM Pfizer and BioNTech to Co-develop Potential COVID-19 Vaccine
Mar 17, 2020 02:00AM Pfizer and BioNTech to Co-Develop Potential COVID-19 Vaccine
Mar 15, 2020 08:15AM Germany tries to halt U.S. interest in firm working on coronavirus vaccine
Mar 13, 2020 03:26PM Pfizer (PFE) Outlines Five-Point Plan to Battle COVID-19
Mar 13, 2020 03:25PM Pfizer Outlines Five-Point Plan to Battle COVID-19
Mar 13, 2020 08:04AM EMD Serono and Pfizer (PFE) Provide Update on Phase III JAVELIN Head and Neck 100 Study
Mar 13, 2020 08:00AM EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study
Mar 4, 2020 08:04AM Pfizer (PFE) Reports Election of Susan Hockfield to Board
Mar 4, 2020 08:00AM Susan Hockfield Elected to Pfizer’s Board of Directors
Mar 2, 2020 06:47AM Pfizer (PFE) and Lilly (LLY) announce FDA accepted for review BLA for tanezumab 2.5 mg administered subcutaneously
Mar 2, 2020 06:45AM U.S. FDA Accepts Regulatory Submission for Tanezumab, a Potential First-in-Class Treatment for Patients with Chronic Pain Due to Moderate-to-Severe Osteoarthritis
Feb 27, 2020 04:15PM James Quincey Elected to Pfizer’s Board of Directors
Feb 27, 2020 08:15AM Mylan and Pfizer Announce Appointment of Viatris Chief Financial Officer
Feb 27, 2020 08:15AM Mylan and Pfizer Announce Appointment of Viatris Chief Financial Officer
Feb 27, 2020 08:00AM Mylan and Pfizer Finalize Appointments to Viatris Board of Directors
Feb 27, 2020 08:00AM Mylan and Pfizer Finalize Appointments to Viatris Board of Directors
Feb 25, 2020 10:00AM Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Feb 18, 2020 06:45AM European Commission Approves VYNDAQEL®, the First Treatment in the EU for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Jan 31, 2020 09:00AM Pfizer (PFE) Receives Positive CHMP Opinion for Oncology Biosimilar, RUXIENCE
Jan 31, 2020 09:00AM Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, RUXIENCE™ (rituximab)
Jan 23, 2020 10:00AM Pfizer Vaccines Launches Global Centers of Excellence Network to Conduct Real-World Research on Vaccine-Preventable Diseases Affecting Adults
Jan 23, 2020 06:45AM Pfizer’s Greenstone and Digital Men’s Health Clinic Roman Collaborate to Offer Patients Remote Access to the Only FDA-Approved Authorized Generic Version of Viagra® (sildenafil citrate)
Jan 13, 2020 07:31AM Biogen (BIIB) to Acquire Novel Clinical Stage Asset with Application in Alzheimer's Disease and Parkinson's Disease from Pfizer Inc. (PFE)
Jan 13, 2020 07:30AM Biogen to Acquire Novel Clinical Stage Asset with Application in Alzheimer’s Disease and Parkinson’s Disease from Pfizer Inc.
Jan 13, 2020 07:30AM Biogen to Acquire Novel Clinical Stage Asset with Application in Alzheimer’s Disease and Parkinson’s Disease from Pfizer Inc.
Jan 7, 2020 10:00AM Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Jan 6, 2020 07:08AM EMD Serono, Pfizer (PFE) Announce BAVENCIO Significantly Improved Overall Survival in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Jan 6, 2020 07:00AM BAVENCIO Significantly Improved Overall Survival in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Dec 23, 2019 08:16AM Theravance Biopharma (TBPH), Pfizer (PFE) Enter Pact for Skin-Targeted, Locally-Acting Pan-Janus Kinase Inhibitor Program
Dec 23, 2019 08:15AM Theravance Biopharma and Pfizer Inc. Enter Global License Agreement for Skin-Targeted, Locally-Acting Pan-Janus Kinase (JAK) Inhibitor Program
Dec 18, 2019 10:33AM Pfizer (PFE) Reports FDA Accepts & Grants Priority Review to sNDA for BRAFTOVI (encorafenib) in Combination with ERBITUX (cetuximab) (BRAFTOVI Doublet)
Dec 18, 2019 10:30AM U.S. FDA Accepts and Grants Priority Review to sNDA for BRAFTOVI® (encorafenib) in Combination with ERBITUX® (cetuximab) (BRAFTOVI Doublet) for the Treatment of BRAFV600E-Mutant Metastatic Colorecta
Dec 18, 2019 08:30AM Pfizer and Mylan Announce Two Future Viatris Board Members
Dec 18, 2019 08:30AM Pfizer and Mylan Announce Two Future Viatris Board Members
Dec 17, 2019 10:00AM Pfizer Invites Public to View and Listen to Webcast of January 28 Conference Call with Analysts
Dec 16, 2019 08:30AM Pfizer Declares First-Quarter 2020 Dividend and Announces Upcoming Investor Day to Highlight Strength of Innovative R&D Pipeline
Dec 13, 2019 08:32AM Pfizer (PFE) Reports Positive CHMP Opinion for VYNDAQEL for Use in Patients with Transthyretin Amyloid Cardiomyopathy
Dec 13, 2019 08:28AM Pfizer Receives Positive CHMP Opinion for VYNDAQEL® for Use in Patients with Transthyretin Amyloid Cardiomyopathy, a Rare and Fatal Disease
Dec 12, 2019 05:12PM Pfizer (PFE) Announces FDA Approves XELJANZ XR (tofacitinib) Extended-Release Tablets for Treatment of Ulcerative Colitis
Dec 12, 2019 05:12PM FDA Approves XELJANZ® XR (tofacitinib) Extended-Release Tablets for the Treatment of Ulcerative Colitis
Dec 9, 2019 06:14AM Sangamo Therapeutics (SGMO), Pfizer (PFE) Report Updated Follow-Up Results from Phase 1/2 Alta Study Evaluating Investigational SB-525 Gene Therapy
Dec 7, 2019 09:00AM Sangamo and Pfizer Announce Updated Phase 1/2 Results Showing Sustained Increased Factor VIII Activity Through 44 Weeks Following SB-525 Gene Therapy Treatment
Nov 19, 2019 04:05PM Akcea and Ionis Announce Closing of Licensing Agreement with Pfizer Inc. for Investigative Antisense Therapy AKCEA-ANGPTL3-L(Rx)
View More Recent Stories View Older Stories